Literature DB >> 27671237

Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients and the Application in Dosing Recommendation.

Xingang Li1, Yuanxing Wu2, Shusen Sun3, Zhigang Zhao1, Qiang Wang4.   

Abstract

Our previous study indicates that cerebrospinal fluid (CSF) albumin level is a determinant of CSF vancomycin concentration for postoperative neurosurgical patients. We aimed to develop an improved vancomycin population pharmacokinetic model with incorporation of more covariates, and to provide dosing guidance for clinicians. Vancomycin was administered intravenously to 20 patients with external ventricular drains after neurosurgical operation. Blood and CSF were collected and vancomycin concentrations were measured by HPLC. A separate CSF compartment was considered, and was linked to the central compartment by a first-order process (QCSF). The clearance of the CSF compartment (ClCSF) was used to characterize vancomycin elimination from CSF through external ventricular drain. Nonlinear mixed-effects modeling approach was used to develop the model. The CSF albumin level (mg/dL) was the covariate influencing QCSF: QCSF=0.0049+0.000021×(CSF albumin-279). The effect of body weight (BW, kg) was significant on central volume (VC): VC=27.84+0.96×(BW-69). All parameters were estimated with an acceptable precision (relative standard error: RSE% < 30.26). The performance of the final model was acceptable with our previous dataset. A simple to use dosage regimen table was created to guide clinicians with vancomycin dosing. This model incorporates variables of both CSF albumin and BW, which offers improvements to the previous pharmacokinetics model.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  CSF albumin; blood-brain barrier; body weight; cerebrospinal fluid; neurosurgical patient; nonlinear mixed-effects modeling; population pharmacokinetics; vancomycin

Mesh:

Substances:

Year:  2016        PMID: 27671237     DOI: 10.1016/j.xphs.2016.08.012

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  Population Pharmacokinetics of Combined Intravenous and Local Intrathecal Administration of Meropenem in Aneurysm Patients with Suspected Intracranial Infections After Craniotomy.

Authors:  Xingang Li; Shusen Sun; Qiang Wang; Zhigang Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

2.  Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration.

Authors:  Xingang Li; Shusen Sun; Xi Ling; Kai Chen; Qiang Wang; Zhigang Zhao
Journal:  Eur J Clin Pharmacol       Date:  2017-08-29       Impact factor: 2.953

3.  Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.

Authors:  Nilesh Kumta; Aaron J Heffernan; Menino Osbert Cotta; Steven C Wallis; Amelia Livermore; Therese Starr; Wai Tat Wong; Gavin M Joynt; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2022-07-06       Impact factor: 5.938

4.  Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients.

Authors:  Jian Wei; Yuwen Zhang; Ze Li; Xingang Li; Chenglong Zhao
Journal:  Ann Transl Med       Date:  2022-06

5.  Population Pharmacokinetic Modeling of Azithromycin Eyedrops in Tears Following Single-Dose Topical Administration in Healthy Volunteers.

Authors:  Feng Wu; Xiuli Zhao; Xingang Li; Yimin Cui
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 6.  An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

Authors:  Abdullah Aljutayli; Amélie Marsot; Fahima Nekka
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

7.  Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.

Authors:  Yan-Xia Yu; Jian Lu; Hao-di Lu; Lan Li; Jing-Jing Li; Lu Shi; Lu-Fen Duan; Zhi-Wei Zhuang; Su-Dong Xue; Yi Shen; Lian Tang
Journal:  Eur J Hosp Pharm       Date:  2021-01-07

8.  Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B.

Authors:  Jingfeng Bi; Xingang Li; Jia Liu; Dawei Chen; Shuo Li; Jun Hou; Yuxia Zhou; Shanwei Zhu; Zhigang Zhao; Enqiang Qin; Zhenman Wei
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

9.  Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Authors:  Nyein Hsu Maung; Janthima Methaneethorn; Thitima Wattanavijitkul; Tatta Sriboonruang
Journal:  Eur J Hosp Pharm       Date:  2021-07-20

10.  Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model.

Authors:  Jinlin Guo; Yayu Huo; Fang Li; Yuanping Li; Zhaojun Guo; Huaqing Han; Yuhong Zhou
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.